• Guilin Pharmaceutical Co., Ltd.

    D-ARTEPP

    Common Name:Dihydroartemisinin and Piperaquine Phosphate Tablets

    It is a compound preparation composed of dihydroartemisinin and piperaquine phosphate, and passed the WHO prequalification in 2019.
    Therapeutic Area: treatment of uncomplicated malaria.

  • Guilin Pharmaceutical Co., Ltd.

    SPAQ-CO® Disp

    Common Name:Sulfadoxine/Pyrimethamine + Amodiaquine (Hydrochloride) Dispersible Tablets

    This product passed the WHO prequalification in 2018 and is the world's first drug for malaria prophylaxis in children approved for seasonal malaria chemoprevention (SMC).
    Therapeutic Area: prophylaxis for malaria.

  • Guilin Pharmaceutical Co., Ltd.

    Artesun®

    Common Name:Artesunate for Injection

    It is a global initiative and the "gold standard" for treatment of severe malaria. It passed the WHO prequalification in 2005, is the first-choice drug for severe malaria recommended by the WHO, and is known as an "anti-malarial miracle drug".
    Therapeutic Area: treatment of severe malaria

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Pyrazinamide Tablets

    Common Name:Pyrazinamide Tablets

    First-line anti-TB drug indicated for the treatment of tuberculosis in combination with other anti-TB drugs (such as streptomycin, isoniazid, rifampicin and ethambutol). a product passed consistency evaluation.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Ethambutol Hydrochloride Tablets

    Common Name:Ethambutol Hydrochloride Tablets

    First-line anti-tuberculosis drug indicated for the treatment of tuberculosis caused by mycobacterium tuberculosis in combination with other anti-tuberculosis drugs; also used for the treatment of tuberculous meningitis and atypical mycobacterial infections; a product passed consistency evaluation.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Isoniazid Tablets

    Common Name:Isoniazid Tablets

    First-line antituberculosis drug indicated for the treatment of various types of TB, including tuberculous meningitis and other mycobacterium tuberculosis infections. The first isoniazid product passed consistency evaluation.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Protionamide Enteric-coated Tablets

    Common Name:Protionamide Enteric-coated Tablets

    Second-line antituberculous drug and the essential therapeutic drug for treatment of drug-resistant tuberculosis by inhibiting the cell wall synthesis of mycobacterium tuberculosis; a required drug for short-course regimen for treatment of drug-resistant tuberculosis.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Rifampicin Capsules

    Common Name:Rifampicin Capsules

    First-line drug for treatment of drug-susceptible tuberculosis; 0.3 g in strength, reduced number of tablets taken by patients and improved compliance; a product passed consistency evaluation.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Fu He

    Common Name:Rifampicin Capsules (II)

    First-line drug for treatment of drug-susceptible tuberculosis; rifampicin with less hepatic impairment and higher bioavailability; achieving the therapeutic effect of 0.6 g of general rifampicin with only two capsules per time.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Rifampin and Isoniazid Tablets

    Common Name:Rifampin and Isoniazid Tablets

    A drug recommended by WHO guidelines in standard treatment regimens for drug-susceptible tuberculosis; improved patient compliance; reduced drug resistance rate.

  • Shenyang Hongqi Pharmaceutical Co., Ltd.

    Yi Nuo Ni Kang

    Common Name:Ethambutol Hydrochloride, Pyrazinamide, Rifampicin and Isoniazid Tablets (II)

    A drug recommended by WHO guidelines in standard treatment regimens for drug-susceptible tuberculosis; the only fixed-dose four-drug combination for tuberculosis treatment included in the WHO Model Lists of Essential Medicines; improved patient compliance; reduced drug resistance rate.

  • Sichuan Hexin Pharmaceutical Co., Ltd.

    Xi Chang/Bi Li Shu

    Common Name:Cefmetazole Sodium for Injection

    It has quality of brand name drug, and is a product under National Medical Insurance Class B; a confidence choice for monotherapy of mixed infection of aerobic bacteria and anaerobic bacteria; simple choice for prevention of surgical infection and perioperative infection; economical choice for empirical therapy of infection of ESBLs-producing bacteria.

  • Dalian Aleph Biomedical Co., Ltd.

    Rabies vaccine for human use

    Common Name:VERO Cell

  • Sichuan Hexin Pharmaceutical Co., Ltd.

    赛复诺

    Common Name:Cefminox Sodium for Injection

    It has quality of brand name drug, and is a product under National Medical Insurance Class B; it is recommended by many guidelines and consensus at home and abroad; it has a broad antibacterial spectrum, covering G+ bacteria, G-bacteria and anaerobic bacteria; it has good stability against ESBL enzymes, and has a low drug resistance rate clinically.

  • YaoPharma Co., Ltd.

    Sha Duo Li Ka

    Common Name:Potassium Sodium Dehydroandrographolide Succinate for Injection

    It is an original product with high brand awareness and the highest market share; it is a chemical drug with simple component and clear structure; it is a lyophilized powder preparation, with good stability, facilitating storage, transportation and use; post-marketing safety reassessment of more than 30,000 cases confirms the high safety of the product.

  • JSK (Suzhou) Pharmaceutical Co., Ltd.

    Heptodin®

    Common Name:Lamivudine Tablets

    It is an original product under National Medical Insurance Class B; it is the first oral anti-HBV drug marketed in China; it has high safety, has strong antiviral ability, and is a classic drug for patients with chronic hepatitis B; long-term treatment with it can effectively improve liver tissue inflammation and delay the progress of chronic hepatitis B disease.

  • Guilin Pharmaceutical Co., Ltd.

    Ka Di

    Common Name:Flucloxacillin Sodium for Injection

    It is indicated for treatment of infection caused by sensitive Gram-positive bacteria, including β-lactamase-producing staphylococci and streptococci.

  • Clindamycin Hydrochloride Capsules

    Common Name:瑞塞宁

    It is a China's national essential drug under National Medical Insurance Class A, and is included in the National Centralized Drug Procurement List; it is recommended by multiple guidelines at home and abroad; it is an antibacterial drug for unrestricted use, and an experience choice for treatment of various common infections.

This information is only intended for reference purposes for medical professionals. If you are not a medical professional, please click the "cancel".

CancelDetermine

c